cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
Endocrine Oncology · 2021
DOI: 10.1530/eo-21-0012 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endocrine Oncology, 2021. Verfasst von Laura Gerard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Départment d'Oncologie Médicale, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well correlated with the disease course, and cfDNA may be used as a predictive marker and/or as an early marker of response. In addition, the absolute count of atypical cells was elevated upon disease progression. Learning points cfDNA changes were well correlated with the Cushing’s syndrome course and with the tumour burden changes assessed by laboratory markers and by RECIST criteria. cfDNA analysis was used to determine the pharmacogenetic patterns of the present patient. An elevated number of atypical circulating cells was noticed upon disease progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Départment d'Oncologie Médicale, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
- European NeuroEndocrine Tumours Society (ENETS) Lyon Center of Excellence, Lyon, France.
- CIRCAN (CIRculating CANcer) Platform, Hospices Civils de Lyon, GHS University Hospital, Pierre-Benite, France.
- Institut Multi-Site de Pathologie et Biologie Moléculaire, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
- Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne Cedex, France.
- INSERM, UMR 1052, Lyon Cancer Research Center, Faculté Laennec, Lyon Cedex 08, France.
Zitieren
APA
Gerard, L., Barthelemy, D., Gauthier, A., Hervieu, V., Lopez, J., Gibert, B., Lasolle, H., Chardon, L., Garcia, J., Raverot, G., Payen, L., & Walter, T. (2021). cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome. Endocrine Oncology. https://doi.org/10.1530/eo-21-0012
Vancouver
Gerard L, Barthelemy D, Gauthier A, Hervieu V, Lopez J, Gibert B, et al. cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome. Endocrine Oncology. 2021. doi:10.1530/eo-21-0012
BibTeX
@article{Gerard2021,
author = {Gerard, Laura and Barthelemy, David and Gauthier, Arnaud and Hervieu, Valerie and Lopez, Jonathan and Gibert, Benjamin and Lasolle, Helene and Chardon, Laurence and Garcia, Jessica and Raverot, Gérald and Payen, Léa and Walter, Thomas},
title = {cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome},
journal = {Endocrine Oncology},
year = {2021},
doi = {10.1530/eo-21-0012}
}
EUVIMED